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Background
Albumin dialysis (AD) is a therapeutic option in severe
cholestatic liver failure. However, it can significantly
enhance drug elimination. Pharmacokinetic data on
antimicrobial agents administered under this clinical
condition are very sparse. Teicoplanin (TP) is a large
glycopeptide, containing six compounds with a molecu-
lar weight between 1,500 and 1,900 Da. TP has a similar
spectrum of activity and similar efficacy compared to
vancomycin. It is active against a variety of bacteria,
such as Streptococci, Staphylococcus aureus including
methicillin-resistant S. aureus (MRSA), Enterococcus
faecalis and E. faecium. TP is eliminated by the kidneys
with a terminal half life of 80–180 h. Its protein binding
is ~90%.
Methods
TP plasma concentrations were measured in a 30-year
old critically ill patient (body weight 50 kg), who was
treated with albumin dialysis because of severe chole-
static liver failure with refractory pruritus and obtained
TP because of recurrent gram-positive sepsis. Albumin
dialysis was performed with the molecular adsorbent
recirculating system (MARS). Two separate cycles of
AD were analysed.
Results
After a 1,200 mg loading dose, doses of 1,200 and
1,000 mg on day 2 and 3, respectively, were adminis-
tered during 2 cycles of AD for achieving TP trough
levels above 10 µg/ml, which are recommended for
most infections. During the first and the second AD
cycle, the TP peak concentrations amounted to 98.7 and
99.8 µg/ml, the trough concentrations 27.0 and 15.7 µg/
ml, the half-life was 4.6 and 6.4 hours, the apparent
volume of distribution 0.28 and 0.32 L/kg and the TP
clearance 43 and 35 mL/h/kg, respectively. TP levels
were about 40% reduced post- vs. prefilter. Within 8
hours of AD, the TP serum concentration decreased by
about 75%. The decline in serum levels is similar to that
observed during continuous veno-venous hemofiltration.
Conclusions
Despite a considerable elimination of TP by AD thera-
peutic serum levels could be maintained during the
entire treatment by administered high doses — exceed-
ing the recommended doses — and close drug
monitoring.
Author details
1Clinical Pharmacokinetics Unit, Laboratory of Inflammation Research,
Department of Internal Medicine I, Innsbruck Medical University, 6020
Innsbruck, Austria.
2Central Institute for Medical and Chemical Laboratory
Diagnostics, Innsbruck General Hospital, 6020 Innsbruck, Austria.
3Intensive
Care Unit, Department of Internal Medicine I, Innsbruck Medical University,
6020 Innsbruck, Austria.
Published: 16 November 2010
doi:10.1186/1471-2210-10-S1-A36
Cite this article as: Weiler et al.: Teicoplanin pharmacokinetics during
albumin dialysis. BMC Pharmacology 2010 10(Suppl 1):A36.
* Correspondence: romuald.bellmann@i-med.ac.at
1Clinical Pharmacokinetics Unit, Laboratory of Inflammation Research,
Department of Internal Medicine I, Innsbruck Medical University, 6020
Innsbruck, Austria
Full list of author information is available at the end of the article
Weiler et al. BMC Pharmacology 2010, 10(Suppl 1):A36
http://www.biomedcentral.com/1471-2210/10/S1/A36
© 2010 Bellmann et al; licensee BioMed Central Ltd.